Neogen Corp: Form 10-Q for the period ended Nov 30, 2023
Filed with the SEC on Jan 9, 2024 and accepted by EDGAR at Jan 9, 2024, 15:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-09-01 to 2023-11-30 | $229.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-06-01 to 2023-11-30 | $458.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-09-01 to 2023-11-30 | $112.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-06-01 to 2023-11-30 | $225.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-09-01 to 2023-11-30 | $116.8m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-06-01 to 2023-11-30 | $233.5m | us-gaap:GrossProfit |
| Research and development | 3 months2023-09-01 to 2023-11-30 | $5.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-06-01 to 2023-11-30 | $12.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-09-01 to 2023-11-30 | $14.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-06-01 to 2023-11-30 | $33.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-09-01 to 2023-11-30 | $10.3m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-06-01 to 2023-11-30 | $20.9m | us-gaap:InterestExpense |
| Income tax | 3 months2023-09-01 to 2023-11-30 | −$260.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-06-01 to 2023-11-30 | −$100.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-09-01 to 2023-11-30 | −$3.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-06-01 to 2023-11-30 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-09-01 to 2023-11-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-06-01 to 2023-11-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-09-01 to 2023-11-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-06-01 to 2023-11-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-09-01 to 2023-11-30 | 216,410,493 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-06-01 to 2023-11-30 | 216,359,511 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-06-01 to 2023-11-30 | $38.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-06-01 to 2023-11-30 | $55.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2023-11-30 | $205.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-11-30 | $624.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-11-30 | $4.60bn | us-gaap:Assets |
| Current liabilities | At period end2023-11-30 | $176.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-11-30 | $1.45bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-11-30 | $886.9m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-11-30 | $2.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-11-30 | $3.15bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-11-30 | 216,520,296 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950170-24-003320. Last ingested by Listed: Oct 30, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.